Mar 232022

Download the abstract book: 5th IAAASS Program & Abstract book








5 – 5:10 PM              Opening Remarks


Convener:                 Enzo Tramontano, University of Cagliari, Italy

                                    Reuben Harris, HHMI and University of Minnesota, United States



5:10 – 6:00 PM          Opening Plenary 


1 – Akiko Iwasaki, Yale School of Medicine, United States “Immune responses to SARS-CoV-2”









9:55 – 10:00 AM        Opening Remarks


Convener:            Reuben Harris, HHMI and University of Minnesota, United States




10:00 – 11:00 AM      Breakout Session 1 –  Individual Breakout Rooms 1-10


2 – Low Zhao Xuan, Sunway University, Malaysia “Antiviral activity of silymarin, baicalein and baicalin against Dengue virus”


3 – Nicolò Santi, Cardiff University, United Kingdom “Identification of novel non-nucleoside inhibitors of Dengue virus NS5 RNA-dependent RNA polymerase”


4 – Saverio Lemme, MIMIT – Tor Vergata, Italy “An application of the obtained comparison results from the analysis of three classes of patients pharmacologically treated and untreated to the structure of the HIV-1 integrase  to obtain a deeper understanding of the observed mutations”


5 – Saumya Singh, Sam Higginbottom University of Agriculture, Technology & amp; Sciences, India “Design and development of novel oxadiazole based 1,3,5-Triazines as NNRTI targeting entrance channel of NNRTI binding site ”


6 – Emmanuel Heilmann, Medical University Innsbruck, Austria “Cell-based cis-cleavage screening method for SARS-CoV-2 protease inhibitors”


7 – Francesca Miglioli, University of Parma, Italy “Synthesis of polyhydroxylated heterocyclic compounds as inhibitors of Influenza virus pan endonuclease”


8 – Dominik Werz, University of Hambur, Germany “Lipophilically, bioreversibly masked cyclic nucleoside monophosphate derivatives – Tools for non-invasive cell assays”


9 – Ekaterina Ryabchevskaya, Lomonosov Moscow State University, Russian Federation “The development of broad‑spectrum recombinant Betacoronavirus vaccine with plant virus‑based platform‑adjuvant”


10 – Annalaura Paulis, University of Cagliari, Italy “Flavonoids induce type I Interferon expression through STING dependent pathway”


11 – Annalaura Brai, University of Siena, Italy “Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor”


12 – Lia-Raluca Olari, Ulm University, Germany “An amyloidogenic fragment of human alpha hemoglobin with a combined antibacterial and antiviral activity”


13 – Selina Pasquero, University of Turin, Italy “Novel antiviral activity of PADs inhibitors against Beta-coronaviruses SARS-CoV-2 and HCoV-OC43”




Main Session 1:       


Convener:                 Cristina Parolin, University of Padua, Italy


11:00 – 11:10 AM                        Overview of the session


11:10 – 11:40 AM            14 – Graciela Andrei, KU Leuven, Belgium “Herpesvirus DNA polymerases and impact of mutator phenotypes”


11:40 – 12:10 AM            15 – Matteo Iannacone, Vita-Salute San Raffaele University, Italy “Controlled administration of aerosolized SARS-CoV-2 to K18-hACE2 transgenic mice uncouples respiratory infection and anosmia from fatal neuroinvasion”


12:10 – 12:40 AM            16 – Ali Mirazimi, Karolinska Institutet, Sweden “Using recombinant human Angiotensin-Converting Enzyme 2  (rhACE-2) as antiviral against SARS-CoV 2”


12:40 AM  – 01:10 PM      17 – Roberto Di Santo, Università di Roma La Sapienza, Italy “Design of selective HIV-1 RNase H inhibitors starting form DKA dual inhibitors of IN and RNase H”


01:10 – 01:40 PM            18 – Andrea Brancale, Cardiff University, United Kingdom “ Structure-based drug design in antiviral drug discovery”





01:40 – 03:00 PM            Long break (breakout rooms 2-18 open for discussion)




Main Session 2:       


Convener:                 Angela Corona, University of Cagliari, Italy


03:00 – 03:10 PM                        Overview of the session


03:10 – 03:40 PM            19 – Jason McLellan, University of Texas Austin, United States “Structural approaches to SARS-CoV-2 therapy and strategies to address the inevitability of resistance”


03:40 – 04:10 PM            20 – Reuben Harris, HHMI and University of Minnesota, United States “Innovative herpesviral mechanisms to escape restriction by cellular APOBEC enzymes”


04:10 – 04:40 PM            21 – Katherine Seley-Radtke, University of Maryland, United States   “Rational (and sometimes irrational!) strategies in nucleoside drug design”


04:40 – 05:10 PM            22 – St. Patrick Reid, Omaha University, United States  “Elucidating the pathogenic mechanisms of chikungunya virus”


05:10 – 05:40 PM            23 – Peter Stockley, University of Leeds, United Kingdom “Structural & functional investigations of a murderous viral enzyme in a native-like context”





05:40 – 06:00 PM            Short break (breakout rooms 19-23 open for discussion)




06:00 – 07:00 PM      Breakout Session 2 –  Individual Breakout Rooms 21-30


24 – Alessia Onali, University of Cagliari, Italy “Inhibitors of HIV-1 RT: exploring new scaffolds for the dual inhibitionof polymerase and ribonuclease associated functions”


25 – Charles Waters, University of Maryland, United States “Synthesis of flexible nucleos(t)ide analogues of remdesivir in broad specturm antiviral therapeutics”


26 – Elisa Fanunza,University of Minnesota, United States “Human cytomegalovirus mediates APOBEC3B relocalization early during infection through a ribonucleotide reductase-independent mechanism”


27 – Luisa Fernanda Duarte Peñaloza, Pontificia Universidad Católica Chile, Chile  “Characterization of vaccine breakthrough cases exhibited in a cohort of Chilean adults immunized with an inactivated SARS-CoV-2 vaccine”


28 – Nathan Ponzar, Saint Louis University, United States “Complex inhibition characteristics of HBV and HIV RibonucleasE H inhibitors against human ribonuclease H1”


29 – Sante Scognamiglio, University of Cagliari, Italy “Identification, comprehensive characterization and comparative genomics of the HERV-K(HML8) integrations in the human genome”


30 – Tyng Hwey Tan, University of Aberdeen, United Kingdom “Monoclonal human antibodies that recognise the exposed N and C terminal regions of the often-overlooked SARS-COV-2 ORF3a transmembrane protein”


31 – Seyad Arad Moghadasi, University of Minnesota, United States “Gain-of-function assay for SARS-CoV-2 Mpro inhibition in living cells”


32 – Desiree Rijono, University of Hamburg, Germany “Optimization of a phenylethynyl anthranilic acid based dihydroorotate dehydrogenase inhibitor series for the use as antiviral agent”


33 – Benedikt Ganter, University of Hamburg, Germany  “Thesis of modified T-1106-5´-triphosphates as potential inhibitors of the SARS-CoV-2 RNA polymerase”


34 – Joy E. Thames, University of Maryland, United States “Design, synthesis, and biological evaluation of flex-acyclovir analogues against SARS-CoV-2”


35 – Oriana Tabarrini, Universiy of Perugia, Italy “Exploiting a proprietary compound library to fight SARS-COV-2: identification of 2-phenylquinolines with pan-anticoronavirus activity”





07:00 – 09:00 PM            Refreshments (breakout rooms 2-35 open for discussion)











11:55 – 12:00 AM      Opening Remarks


Convener:            Enzo Tramontano, University of Cagliari, Italy




Main Session 3:       


Convener:                 Elias Maccioni, University of Cagliari, Italy


12:00 – 12:10 AM                        Overview of the session


12:10 – 12:40 AM            36 – Giorgio Gribaudo, University of Torino, Italy “The US12 protein family of the Human Cytomegalovirus: from functions to antiviral intervention”


12:40 AM – 01:10 PM       37 – Branka Horvat, International Center for Infectiology Research-CIRI, France “Development of fusion inhibitory peptides against airborne viral infections, measles and COVID-19”


01:10 – 01:40 PM            38 – Luis Menendez- Arias, Centro de Biología Molecular Severo Ochoa, Madrid, Spain “HIV-1 replication: fidelity, drug resistance and unexploited antiviral targets”


01:40 – 02:10 PM            39 – Vincenzo Summa, Federico II University, Italy “A journey from HCV protease to SARS-CoV-2- 3Clp protease inhibitors in clinical trial: challenges and opportunities”


02:10 – 02:40 PM            40 – Johan Neyts, KU Leuven, Belgium “Antivirals, a lot has been achieved, yet a long way to go”




02:40 –04:00 PM             Long break (breakout rooms 36-40 open for discussion)




Main Session 4:       


Convener:                 Reuben Harris, HHMI and University of Minnesota, United States   


04:00 – 04:10 PM                        Overview of the session


04:10 – 04:40 PM            41 – Anne Simon, University of Maryland, United States   “Developing novel virus-like agents to combat viral, bacterial, and other pathogens of trees to prevent a future without citrus, chocolate, grapevines and olives”


04:40 – 05:10 PM            42 – Yun-Xing Wang, National Cancer Institute, United States   “Direct visualization of individual RNA molecules and mapping the RNA conformational space in solution”


05:10 – 05:40 PM            43 – Josè Estè Araque, UIC, Spain “Identifying new antivirals, resistance and host-factors”


05:40 – 06:10 PM            44 – Michelle Hastings, Rosalind Franklin University, United States   “Antisense oligonucleotides for the control of gene expression in disease and infection”


06:10 – 06:40 PM            45 – Luca Guidotti, Vita-Salute San Raffaele University, Italy “Animal models for the development of antiviral agents against hepatitis B virus (HBV)”






06:40 – 08:00 PM            Refreshments (breakout rooms 36-45 open for discussion)




credits Università degli Studi di Cagliari
C.F.: 80019600925 - P.I.: 00443370929
note legali | privacy